The many faces of PPARγ

Cell

Volumn 123, Issue 6, 2005, Pages 993-999

  Lehrke, Michael ^a   Lazar, Mitchell A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMILORIDE; ANTIDIABETIC AGENT; CELL NUCLEUS RECEPTOR; DIURETIC AGENT; ETOPOSIDE; LIGAND; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROSCLEROSIS; BODY WEIGHT; CANCER; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL METABOLISM; CYTOLOGY; DIABETES MELLITUS; ENTERITIS; GENE TARGETING; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MACROPHAGE; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; RISK ASSESSMENT; ANIMAL; METABOLISM; NEOPLASM; PHYSIOLOGY;

ADIPOCYTES; ANIMALS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; HUMANS; INFLAMMATION; INSULIN RESISTANCE; NEOPLASMS; OBESITY; PPAR GAMMA;

EID: 28944446431     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2005.11.026     Document Type: Review

References (77)

1. Y. Barak, M.C. Nelson, E.S. Ong, Y.Z. Jones, P. Ruiz-Lozano, K.R. Chien, A. Koder, and R.M. Evans PPAR gamma is required for placental, cardiac, and adipose tissue development Mol. Cell 4 1999 585 595
2. I. Barroso, M. Gurnell, V.E. Crowley, M. Agostini, J.W. Schwabe, M.A. Soos, G.L. Maslen, T.D. Williams, H. Lewis, and A.J. Schafer Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension Nature 402 1999 880 883
3. L.C. Bell-Parikh, T. Ide, J.A. Lawson, P. McNamara, M. Reilly, and G.A. FitzGerald Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma J. Clin. Invest. 112 2003 945 955
4. J. Berger, M.D. Leibowitz, T.W. Doebber, A. Elbrecht, B. Zhang, G. Zhou, C. Biswas, C.A. Cullinan, N.S. Hayes, and Y. Li Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects J. Biol. Chem. 274 1999 6718 6725
5. G. Boden, X. Chen, J. Ruiz, J.V. White, and L. Rossetti Mechanisms of fatty acid-induced inhibition of glucose uptake J. Clin. Invest. 93 1994 2438 2446
6. L. Chao, B. Marcus-Samuels, M.M. Mason, J. Moitra, C. Vinson, E. Arioglu, O. Gavrilova, and M.L. Reitman Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones J. Clin. Invest. 106 2000 1221 1228
7. A. Chawla, E.J. Schwarz, D.D. Dimaculangan, and M.A. Lazar Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation Endocrinology 135 1994 798 800
8. A. Chawla, W.A. Boisvert, C.H. Lee, B.A. Laffitte, Y. Barak, S.B. Joseph, D. Liao, L. Nagy, P.A. Edwards, and L.K. Curtiss A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis Mol. Cell 7 2001 161 171
9. A. Chawla, J.J. Repa, R.M. Evans, and D.J. Mangelsdorf Nuclear receptors and lipid physiology: opening the X-files Science 294 2001 1866 1870
10. G. Chinetti, S. Lestavel, V. Bocher, A.T. Remaley, B. Neve, I.P. Torra, E. Teissier, A. Minnich, M. Jaye, and N. Duverger PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nat. Med. 7 2001 53 58
11. P.C. Chui, H.P. Guan, M. Lehrke, and M.A. Lazar PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1 J. Clin. Invest. 115 2005 2244 2256
12. S.S. Deeb, L. Fajas, M. Nemoto, J. Pihlajamaki, L. Mykkanen, J. Kuusisto, M. Laakso, W. Fujimoto, and J. Auwerx A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity Nat. Genet. 20 1998 284 287
13. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688
14. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688
15. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lefebvre, and G.D. Murray Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
16. R.H. Eckel, S.M. Grundy, and P.Z. Zimmet The metabolic syndrome Lancet 365 2005 1415 1428
17. B.I. Frohnert, T.Y. Hui, and D.A. Bernlohr Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene J. Biol. Chem. 274 1999 3970 3977
18. C. Grommes, G.E. Landreth, and M.T. Heneka Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists Lancet Oncol. 5 2004 419 429
19. H.P. Guan, T. Ishizuka, P.C. Chui, M. Lehrke, and M.A. Lazar Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes Genes Dev. 19 2005 453 461
20. H.P. Guan, Y. Li, M.V. Jensen, C.B. Newgard, C.M. Steppan, and M.A. Lazar A futile metabolic cycle activated in adipocytes by antidiabetic agents Nat. Med. 8 2002 1122 1128
21. Y. Guan, C. Hao, D.R. Cha, R. Rao, W. Lu, D.E. Kohan, M.A. Magnuson, R. Redha, Y. Zhang, and M.D. Breyer Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption Nat. Med. 11 2005 861 866
22. W. He, Y. Barak, A. Hevener, P. Olson, D. Liao, J. Le, M. Nelson, E. Ong, J.M. Olefsky, and R.M. Evans Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle Proc. Natl. Acad. Sci. USA 100 2003 15712 15717
23. A.L. Hevener, W. He, Y. Barak, J. Le, G. Bandyopadhyay, P. Olson, J. Wilkes, R.M. Evans, and J. Olefsky Muscle-specific Pparg deletion causes insulin resistance Nat. Med. 9 2003 1491 1497
24. T. Hibuse, N. Maeda, T. Funahashi, K. Yamamoto, A. Nagasawa, W. Mizunoya, K. Kishida, K. Inoue, H. Kuriyama, and T. Nakamura Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase Proc. Natl. Acad. Sci. USA 102 2005 10993 10998
25. E. Hu, J.B. Kim, P. Sarraf, and B.M. Spiegelman Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma Science 274 1996 2100 2103
26. X. Hu, and M.A. Lazar The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors Nature 402 1999 93 96
27. E.E. Kershaw, and J.S. Flier Adipose tissue as an endocrine organ J. Clin. Endocrinol. Metab. 89 2004 2548 2556
28. H. Koutnikova, T.A. Cock, M. Watanabe, S.M. Houten, M.F. Champy, A. Dierich, and J. Auwerx Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice Proc. Natl. Acad. Sci. USA 100 2003 14457 14462
29. N. Kubota, Y. Terauchi, H. Miki, H. Tamemoto, T. Yamauchi, K. Komeda, S. Satoh, R. Nakano, C. Ishii, and T. Sugiyama PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance Mol. Cell 4 1999 597 609
30. A.M. Lefebvre, I. Chen, P. Desreumaux, J. Najib, J.C. Fruchart, K. Geboes, M. Briggs, R. Heyman, and J. Auwerx Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice Nat. Med. 4 1998 1053 1057
31. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 270 1995 12953 12956
32. A.C. Li, and C.K. Glass The macrophage foam cell as a target for therapeutic intervention Nat. Med. 8 2002 1235 1242
33. A.C. Li, K.K. Brown, M.J. Silvestre, T.M. Willson, W. Palinski, and C.K. Glass Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J. Clin. Invest. 106 2000 523 531
34. M. Li, G. Pascual, and C.K. Glass Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene Mol. Cell. Biol. 20 2000 4699 4707
35. A.C. Li, C.J. Binder, A. Gutierrez, K.K. Brown, C.R. Plotkin, J.W. Pattison, A.F. Valledor, R.A. Davis, T.M. Willson, and J.L. Witztum Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma J. Clin. Invest. 114 2004 1564 1576
36. Y. Li, and M.A. Lazar Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2 Mol. Endocrinol. 16 2002 1040 1048
37. O.A. MacDougald, and S. Mandrup Adipogenesis: forces that tip the scales Trends Endocrinol. Metab. 13 2002 5 11
38. N. Marx, T. Bourcier, G.K. Sukhova, P. Libby, and J. Plutzky PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease Arterioscler. Thromb. Vasc. Biol. 19 1999 546 551
39. K. Matsusue, M. Haluzik, G. Lambert, S.H. Yim, O. Gavrilova, J.M. Ward, B. Brewer Jr., M.L. Reitman, and F.J. Gonzalez Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes J. Clin. Invest. 111 2003 737 747
40. T.M. McIntyre, A.V. Pontsler, A.R. Silva, A. St Hilaire, Y. Xu, J.C. Hinshaw, G.A. Zimmerman, K. Hama, J. Aoki, H. Arai, and G.D. Prestwich Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist Proc. Natl. Acad. Sci. USA 100 2003 131 136
41. N.J. McKenna, and B.W. O'Malley Combinatorial control of gene expression by nuclear receptors and coregulators Cell 108 2002 465 474
42. G. Medina-Gomez, S. Virtue, C. Lelliott, R. Boiani, M. Campbell, C. Christodoulides, C. Perrin, M. Jimenez-Linan, M. Blount, and J. Dixon The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform Diabetes 54 2005 1706 1716
43. P.D. Miles, Y. Barak, W. He, R.M. Evans, and J.M. Olefsky Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency J. Clin. Invest. 105 2000 287 292
44. J. Minamikawa, S. Tanaka, M. Yamauchi, D. Inoue, and H. Koshiyama Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes J. Clin. Endocrinol. Metab. 83 1998 1818 1820
45. S. Mudaliar, A.R. Chang, and R.R. Henry Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications Endocr. Pract. 9 2003 406 416
46. L. Nagy, P. Tontonoz, J.G. Alvarez, H. Chen, and R.M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma Cell 93 1998 229 240
47. J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N. Engl. J. Med. 331 1994 1188 1193
48. A.W. Norris, L. Chen, S.J. Fisher, I. Szanto, M. Ristow, A.C. Jozsi, M.F. Hirshman, E.D. Rosen, L.J. Goodyear, and F.J. Gonzalez Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones J. Clin. Invest. 112 2003 608 618
49. A. Okuno, H. Tamemoto, K. Tobe, K. Ueki, Y. Mori, K. Iwamoto, K. Umesono, Y. Akanuma, T. Fujiwara, and H. Horikoshi Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats J. Clin. Invest. 101 1998 1354 1361
50. G. Pascual, A.L. Fong, S. Ogawa, A. Gamliel, A.C. Li, V. Perissi, D.W. Rose, T.M. Willson, M.G. Rosenfeld, and C.K. Glass A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma Nature 437 2005 759 763
51. F. Picard, M. Gehin, J. Annicotte, S. Rocchi, M.F. Champy, B.W. O'Malley, P. Chambon, and J. Auwerx SRC-1 and TIF2 control energy balance between white and brown adipose tissues Cell 111 2002 931 941
52. S.M. Rangwala, and M.A. Lazar Peroxisome proliferator-activated receptor gamma in diabetes and metabolism Trends Pharmacol. Sci. 25 2004 331 336
53. S.M. Rangwala, B. Rhoades, J.S. Shapiro, A.S. Rich, J.K. Kim, G.I. Shulman, K.H. Kaestner, and M.A. Lazar Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity Dev. Cell 5 2003 657 663
54. M.J. Reginato, S.T. Bailey, S.L. Krakow, C. Minami, S. Ishii, H. Tanaka, and M.A. Lazar A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties J. Biol. Chem. 273 1998 32679 32684
55. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
56. S. Rocchi, F. Picard, J. Vamecq, L. Gelman, N. Potier, D. Zeyer, L. Dubuquoy, P. Bac, M.F. Champy, and K.D. Plunket A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity Mol. Cell 8 2001 737 747
57. E.D. Rosen, P. Sarraf, A.E. Troy, G. Bradwin, K. Moore, D.S. Milstone, B.M. Spiegelman, and R.M. Mortensen PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro Mol. Cell 4 1999 611 617
58. E. Saez, P. Tontonoz, M.C. Nelson, J.G. Alvarez, U.T. Ming, S.M. Baird, V.A. Thomazy, and R.M. Evans Activators of the nuclear receptor PPARgamma enhance colon polyp formation Nat. Med. 4 1998 1058 1061
59. P. Sarraf, E. Mueller, D. Jones, F.J. King, D.J. DeAngelo, J.B. Partridge, S.A. Holden, L.B. Chen, S. Singer, C. Fletcher, and B.M. Spiegelman Differentiation and reversal of malignant changes in colon cancer through PPARgamma Nat. Med. 4 1998 1046 1052
60. P. Sarraf, E. Mueller, W.M. Smith, H.M. Wright, J.B. Kum, L.A. Aaltonen, A. de la Chapelle, B.M. Spiegelman, and C. Eng Loss-of-function mutations in PPAR gamma associated with human colon cancer Mol. Cell 3 1999 799 804
61. K. Schoonjans, J. Peinado-Onsurbe, A.M. Lefebvre, R.A. Heyman, M. Briggs, S. Deeb, B. Staels, and J. Auwerx PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene EMBO J. 15 1996 5336 5348
62. F.J. Schopfer, Y. Lin, P.R. Baker, T. Cui, M. Garcia-Barrio, J. Zhang, K. Chen, Y.E. Chen, and B.A. Freeman Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand Proc. Natl. Acad. Sci. USA 102 2005 2340 2345
63. Y. Shang, and M. Brown Molecular determinants for the tissue specificity of SERMs Science 295 2002 2465 2468
64. D.S. Straus, G. Pascual, M. Li, J.S. Welch, M. Ricote, C.H. Hsiang, L.L. Sengchanthalangsy, G. Ghosh, and C.K. Glass 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway Proc. Natl. Acad. Sci. USA 97 2000 4844 4849
65. C.G. Su, X. Wen, S.T. Bailey, W. Jiang, S.M. Rangwala, S.A. Keilbaugh, A. Flanigan, S. Murthy, M.A. Lazar, and G.D. Wu A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response J. Clin. Invest. 104 1999 383 389
66. P. Tontonoz, E. Hu, R.A. Graves, A.I. Budavari, and B.M. Spiegelman mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer Genes Dev. 8 1994 1224 1234
67. P. Tontonoz, E. Hu, and B.M. Spiegelman Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor Cell 79 1994 1147 1156
68. P. Tontonoz, E. Hu, J. Devine, E.G. Beale, and B.M. Spiegelman PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene Mol. Cell. Biol. 15 1995 351 357
69. J. Tordjman, G. Chauvet, J. Quette, E.G. Beale, C. Forest, and B. Antoine Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells J. Biol. Chem. 278 2003 18785 18790
70. I. Tzameli, H. Fang, M. Ollero, H. Shi, J.K. Hamm, P. Kievit, A.N. Hollenberg, and J.S. Flier Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes J. Biol. Chem. 279 2004 36093 36102
71. J.S. Welch, M. Ricote, T.E. Akiyama, F.J. Gonzalez, and C.K. Glass PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages Proc. Natl. Acad. Sci. USA 100 2003 6712 6717
72. K.E. Wellen, and G.S. Hotamisligil Obesity-induced inflammatory changes in adipose tissue J. Clin. Invest. 112 2003 1785 1788
73. L. Wilson-Fritch, S. Nicoloro, M. Chouinard, M.A. Lazar, P.C. Chui, J. Leszyk, J. Straubhaar, M.P. Czech, and S. Corvera Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone J. Clin. Invest. 114 2004 1281 1289
74. H.E. Xu, T.B. Stanley, V.G. Montana, M.H. Lambert, B.G. Shearer, J.E. Cobb, D.D. McKee, C.M. Galardi, K.D. Plunket, and R.T. Nolte Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha Nature 415 2002 813 817
75. D. Yamashita, T. Yamaguchi, M. Shimizu, N. Nakata, F. Hirose, and T. Osumi The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain Genes Cells 9 2004 1017 1029
76. H. Zhang, A. Zhang, D.E. Kohan, R.D. Nelson, F.J. Gonzalez, and T. Yang Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention Proc. Natl. Acad. Sci. USA 102 2005 9406 9411
77. J. Zhang, M. Fu, T. Cui, C. Xiong, K. Xu, W. Zhong, Y. Xiao, D. Floyd, J. Liang, and E. Li Selective disruption of PPARg2 impairs the development of adipose tissue and insulin sensitivity Proc. Natl. Acad. Sci. USA 101 2004 10703 10708